Published in Fundam Clin Pharmacol on October 01, 2007
Rediscovery of nefopam for the treatment of neuropathic pain. Korean J Pain (2014) 1.17
Enhancement of Antinociception by Co-administrations of Nefopam, Morphine, and Nimesulide in a Rat Model of Neuropathic Pain. Korean J Pain (2012) 1.16
Effects of nefopam on streptozotocin-induced diabetic neuropathic pain in rats. Korean J Pain (2014) 0.95
Intravenous Nefopam Reduces Postherpetic Neuralgia during the Titration of Oral Medications. Korean J Pain (2013) 0.94
Comparison of meperidine and nefopam for prevention of shivering during spinal anesthesia. Korean J Anesthesiol (2013) 0.92
Nefopam Reduces Dysesthesia after Percutaneous Endoscopic Lumbar Discectomy. Korean J Pain (2016) 0.84
Status epilepticus caused by nefopam. J Korean Neurosurg Soc (2014) 0.79
Slow injection of nefopam reduces pain intensity associated with intravenous injection: a prospective randomized trial. J Anesth (2013) 0.79
The analgesic effect of nefopam combined with low dose remifentanil in patients undergoing middle ear surgery under desflurane anesthesia: a randomized controlled trial. Korean J Anesthesiol (2015) 0.77
The Effect of Nefopam on Postoperative Fentanyl Consumption: A Randomized, Double-blind Study. Korean J Pain (2016) 0.75
Use of Nefopam in Perioperative Pain Management; Keeping Nefopam in between. Korean J Pain (2016) 0.75
Opioid sparing effect and safety of nefopam in patient controlled analgesia after laparotomy: A randomized, double blind study. J Int Med Res (2016) 0.75
The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J (1999) 5.44
Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk, and Vav. Mol Cell Biol (1994) 5.02
Prescription of drugs during pregnancy in France. Lancet (2000) 4.12
Maximum likelihood positioning in the scintillation camera using depth of interaction. IEEE Trans Med Imaging (1993) 3.00
Cortical motor reorganization in akinetic patients with Parkinson's disease: a functional MRI study. Brain (2000) 2.06
Adverse drug reactions in patients older than 70 years during the heat wave occurred in France in summer 2003: A study from the French PharmacoVigilance Database. Pharmacoepidemiol Drug Saf (2006) 1.96
Bone metastases from differentiated thyroid carcinoma. Endocr Relat Cancer (2008) 1.88
A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer (2012) 1.64
[Pharmacovigilance of self-medication]. Therapie (1997) 1.54
Bevacizumab-induced serious side-effects: a review of the French pharmacovigilance database. Eur J Clin Pharmacol (2012) 1.52
Guidelines for standard and diuretic renography in children. Eur J Nucl Med (2001) 1.37
Prevalence of orthostatic hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatry (1997) 1.36
Water drinking and the heart. Lancet (1999) 1.34
Antivertigo medications and drug-induced vertigo. A pharmacological review. Drugs (1995) 1.33
Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis (2009) 1.30
Perception of the risk of adverse drug reactions: differences between health professionals and non health professionals. Br J Clin Pharmacol (2002) 1.27
Retroperitoneal fibrosis and treatment of Parkinson's disease with high doses of bromocriptine. Clin Neuropharmacol (1986) 1.25
Sleep attacks and Parkinson's disease treatment. Lancet (2000) 1.25
The ipsilateral cerebellar hemisphere is overactive during hand movements in akinetic parkinsonian patients. Brain (1997) 1.23
Adrenergic supersensitivity in parkinsonians with orthostatic hypotension. Eur J Clin Invest (1990) 1.18
Detection and incidence of drug-induced liver injuries in hospital: a prospective analysis from laboratory signals. Br J Clin Pharmacol (2000) 1.18
Effects of yohimbine on submaxillary salivation in dogs. Br J Pharmacol (1989) 1.15
Supplementary and primary sensory motor area activity in Parkinson's disease. Regional cerebral blood flow changes during finger movements and effects of apomorphine. Arch Neurol (1992) 1.13
The reliability measurements of lateral scapular slide test at three different degrees of shoulder joint abduction. Br J Sports Med (2008) 1.10
Abnormal ocular movements in Parkinson's disease. Evidence for involvement of dopaminergic systems. Brain (1989) 1.09
Pharmacological prospects for alpha 2-adrenoceptor antagonist therapy. Trends Pharmacol Sci (1992) 1.09
Guidelines for 99mTc-DMSA scintigraphy in children. Eur J Nucl Med (2001) 1.08
Prescription of drugs during pregnancy: a study using EFEMERIS, the new French database. Eur J Clin Pharmacol (2009) 1.08
Effect of ropinirole on sleep onset: a randomized, placebo-controlled study in healthy volunteers. Neurology (2002) 1.07
Yohimbine increases human salivary secretion. Br J Clin Pharmacol (1989) 1.07
Beta-3 adrenoceptor-mediated increase in cutaneous blood flow in the dog. J Pharmacol Exp Ther (1994) 1.04
Superior oblique tenectomy in Brown's syndrome. Ophthalmology (1982) 1.04
Severe necrotizing soft-tissue infections and nonsteroidal anti-inflammatory drugs. Clin Exp Dermatol (2008) 1.03
Lipolytic effects of conventional beta 3-adrenoceptor agonists and of CGP 12,177 in rat and human fat cells: preliminary pharmacological evidence for a putative beta 4-adrenoceptor. Br J Pharmacol (1997) 1.03
The positive chronotropic effect induced by BRL 37344 and CGP 12177, two beta-3 adrenergic agonists, does not involve cardiac beta adrenoceptors but baroreflex mechanisms. J Pharmacol Exp Ther (1992) 1.03
Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia. Brain (1998) 1.03
Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease. Mov Disord (2001) 1.01
Square wave jerks in parkinsonian syndromes. J Neurol Neurosurg Psychiatry (1991) 1.01
Arterial and venous thromboembolic events during anti-TNF therapy: a study of 85 spontaneous reports in the period 2000-2006. Biomed Mater Eng (2009) 1.00
Odorous urine in man after asparagus. Br J Clin Pharmacol (1989) 1.00
Yohimbine increases submaxillary kallikrein release into the saliva in dogs: evidence for alpha 2-adrenoceptor-mediated inhibition of cholinergic pathways. Br J Pharmacol (1991) 0.99
Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management. Drugs Aging (2001) 0.99
Ambulatory blood pressure in patients with Parkinson's disease without and with orthostatic hypotension. Clin Auton Res (1992) 0.99
[Drug-induced hiccup: a review of the France pharmacologic vigilance database]. Therapie (1999) 0.99
Perception of risk of adverse drug reactions by medical students: influence of a 1 year pharmacological course. Br J Clin Pharmacol (2007) 0.97
Normal activation of the supplementary motor area in patients with Parkinson's disease undergoing long-term treatment with levodopa. J Neurol Neurosurg Psychiatry (1994) 0.97
The human GRB2 and Drosophila Drk genes can functionally replace the Caenorhabditis elegans cell signaling gene sem-5. Mol Biol Cell (1993) 0.96
[Drug vigilance: opinion survey among residents of a university hospital]. Therapie (1995) 0.96
Proteins with SH2 and SH3 domains couple receptor tyrosine kinases to intracellular signalling pathways. Philos Trans R Soc Lond B Biol Sci (1993) 0.95
Analysis of patients' narratives posted on social media websites on benfluorex's (Mediator® ) withdrawal in France. J Clin Pharm Ther (2013) 0.94
L-Dopa-induced sedation: a double-blind cross-over controlled study versus triazolam and placebo in healthy volunteers. Clin Neuropharmacol (1999) 0.94
Purification of murine IgG3 and IgM monoclonal antibodies by euglobulin precipitation. J Immunol Methods (1988) 0.94
"Medicamentation" of society, non-diseases and non-medications: a point of view from social pharmacology. Eur J Clin Pharmacol (2005) 0.94
Excyclotropia of the nonparetic eye in unilateral superior oblique muscle paralysis. Am J Ophthalmol (1982) 0.93
Buprenorphine in pregnant opioid-dependent women: first results of a prospective study. Addiction (2004) 0.92
Guidelines for glomerular filtration rate determination in children. Eur J Nucl Med (2001) 0.92
Drug-induced myoclonus: a French pharmacovigilance database study. Neurophysiol Clin (2007) 0.91
Value of bone scintiscan for diagnosis of arterial prosthesis infection: preliminary results. Ann Vasc Surg (2000) 0.91
Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study. J Neural Transm (Vienna) (2003) 0.91
Alpha-adrenolytic properties of bromocriptine in dogs. Arch Int Pharmacodyn Ther (1982) 0.91
Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody. J Nucl Med (1998) 0.91
Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease. Mov Disord (1994) 0.91
Long-term prediction of major ischemic events by exercise thallium-201 single-photon emission computed tomography. Incremental prognostic value compared with clinical, exercise testing, catheterization and radionuclide angiographic data. J Am Coll Cardiol (1995) 0.91
[Drug-induced alopecia: review of the literature]. Therapie (1995) 0.90
Photosensitivity to ketoprofen: mechanisms and pharmacoepidemiological data. Drug Saf (2000) 0.90
Apomorphine test in parkinsonian syndromes. Lancet (1990) 0.90
Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb Res (1991) 0.90
Non-adjuvanted 2009 influenza A (H1N1)v vaccine in pregnant women: the results of a French prospective descriptive study. Vaccine (2011) 0.90
[Cerebral hemodynamics and clinical pharmacology in Parkinson disease]. Therapie (1988) 0.90
[Effect of bromocriptine on cerebral blood flow in Parkinson's disease]. Rev Neurol (Paris) (1988) 0.90
A study of salivary secretion in Parkinson's disease. Clin Neuropharmacol (1999) 0.90
Nicardipine causes sympathetic activation that does not involve baroreceptor reflex tachycardia in conscious sinoaortic-denervated dogs. Eur J Pharmacol (1987) 0.89
Review: Magnetic resonance imaging of normal and osteoarthritic cartilage. Arthritis Rheum (1998) 0.89
Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Clin Neuropharmacol (1996) 0.88
Was the thrombotic risk of rofecoxib predictable from the French Pharmacovigilance Database before 30 September 2004? Eur J Clin Pharmacol (2008) 0.88
T2 mapping: an efficient MR quantitative technique to evaluate spontaneous cartilage repair in rat patella. Osteoarthritis Cartilage (2004) 0.88
Yohimbine increases salivary secretion in depressed patients treated with tricyclic antidepressants. Eur J Clin Pharmacol (1990) 0.88
The pharmacologic treatment of gait ignition failure. Adv Neurol (2001) 0.88
Parkinson's disease and weight loss: a study with anthropometric and nutritional assessment. Clin Auton Res (1992) 0.87
[Adverse effects of anticancer drugs: apropos of a pharmacovigilance study at a specialized oncology institution]. Therapie (2001) 0.87
Adverse drug reactions to selegiline: a review of the French pharmacovigilance database. Clin Neuropharmacol (2001) 0.87
A pilot study of N-methyl-D-aspartate (NMDA) antagonist in Parkinson's disease. J Neurol Neurosurg Psychiatry (1992) 0.87
Long-term treatment of Parkinson's disease with bromocriptine. J Neurol Neurosurg Psychiatry (1979) 0.87
Nonsteroidal anti-inflammatory drug-induced liver injury: a case-control study in primary care. Fundam Clin Pharmacol (2004) 0.87
Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (celecoxib and rofecoxib): a case/non-case study from the French Pharmacovigilance Database. Eur J Clin Pharmacol (2004) 0.87
A pharmacoeconomic evaluation of botulinum toxin in the treatment of spasmodic torticollis. Clin Neuropharmacol (2001) 0.86
Differential regulation of fat cell beta-2 and beta-1 adrenoceptors by endogenous catecholamines in dog. J Pharmacol Exp Ther (1989) 0.86
Sublingual apomorphine in Parkinson's disease: a clinical and pharmacokinetic study. Clin Neuropharmacol (1991) 0.86
Pseudophaeochromocytoma in parkinsonian patient treated with fluoxetine plus selegiline. Lancet (1993) 0.86
2009 H1N1 influenza vaccines in pregnant women: the French Pharmacovigilance survey. Vaccine (2010) 0.85
Valvular heart disease in a patient taking benfluorex. Fundam Clin Pharmacol (2006) 0.85
Alpha-2 adrenoceptors in lipolysis: alpha 2 antagonists and lipid-mobilizing strategies. Am J Clin Nutr (1992) 0.85
Sleep attacks and antiparkinsonian drugs: a pilot prospective pharmacoepidemiologic study. Clin Neuropharmacol (2001) 0.85